Applied DNA Sciences Inc (NASDAQ:APDN) shares closed 0.31% on Friday to $3.20. Share prices have been trading in a 52-week range of $2.35 to $9.70. The company has a market cap of $77.29 million at 24.08 million shares outstanding.
Applied DNA Sciences is a company that provides DNA security and authentication solutions and services that help protect products, brands, supply chains and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. It is also engaged in the production of specific DNA sequences using the polymerase chain reaction.
The company’s products include SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, Sentry, digitalDNA and SmokeCloak DNA which are used in various industries, including microcircuits and other electronics, cash-in-transit, textiles and apparel, home asset marking, automotive, printing and packaging, homeland security, law enforcement, identity cards and other secure documents, industrial materials, agrochemicals, pharmaceuticals, consumer products, food and beverage, fine wine, and art and collectibles.
Applied DNA Sciences could be under the spotlight this week since the company is scheduled to present at the 2016 Gateway Conference on September 7-8 at the Four Seasons Hotel in San Francisco. In particular, the company will make its presentation on September 8 at 2:30 pm Pacific Time and a webcast will be available in the Investor Relations section of Applied DNA’s website at www.adnas.com or on the Gateway Conference website at www.gateway-conference.com/presenters.
Any new product announcements or upbeat remarks on their current offerings could lend more upside to the current stock price, which is still close to the bottom of its yearly range. Its line of products have a wide stream of applications and increased commercialization could be positive for its bottom line numbers in the current quarter. The company reported weaker than expected earnings data for the period ending June 30, 2016.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.